Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Phase II NCT04954859

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) — Active Not Recruiting • Phase II • Gastroenterology • NCT04954859.

📅 24 Jun 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase II
NCT ID
NCT04954859
Start
2021-12-14
Completion
2029-01-24
ClinicaliQ Trial Snapshot
  • Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) — Active Not Recruiting • Phase II • Gastroenterology • NCT04954859.
  • B-Sure Trial Summary.
  • This study tracks how long the benefits of bepirovirsen (an experimental hepatitis B treatment) last in patients after they stop taking it.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear [209668: NCT04449029], B-Together [209348: NCT04676724], B-Fine [212602: NCT04544956], B-Well 1 [202009: NCT05630807], B-Well 2 [219288: NCT05630820], and TH HBV ASO-001 [217023: NCT05276297]). Participants will be categorized…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
How to check whether you have bowel cancer
Gastroenterology · BBC Health · 12 Feb 2026
What are the main symptoms and causes of bowel cancer, and how can you reduce your risk of getting it? This update…
View brief →
Guideline
Hepatitis B (Chronic): Diagnosis and Management (NICE NG133)
Gastroenterology · 27 Mar 2026
Assess all newly diagnosed chronic hepatitis B patients with HBsAg, anti-HBc, HBeAg, anti-HBe, quantitative HBV DNA, ALT, and liver function tests before…
View guideline →
Clinical Brief
‘I used delivery apps to hide the shame of alcoholism’
Gastroenterology · BBC Health · 24 Apr 2026
Alcohol addiction can be masked through anonymous delivery services, making problematic drinking less visible to family, friends, and healthcare providers—a barrier to…
View brief →
Clinical Brief
England set to eliminate hepatitis C
Gastroenterology · BBC Health · 10 Aug 2026
Hepatitis C Elimination in England England is progressing toward hepatitis C elimination, positioning itself among the world's first countries to achieve this…
View brief →
Drug Science
The IL-17/IL-23 Axis
Dermatology · 04 Apr 2026
The IL-17/IL-23 Axis is a clinically relevant Drug Science explainer. The IL-23/IL-17 axis is a central driver of immune-mediated inflammatory disease. IL-23,…
Explore mechanism →
Guideline
2022 EASL Clinical Practice Guidelines on Hepatitis C
Gastroenterology · 30 Mar 2026
This EASL guideline addresses 2022 EASL Clinical Practice Guidelines on Hepatitis C in Gastroenterology. Use it to review current recommendation wording, eligibility…
View guideline →